• 1
    Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D. Measuring chemotherapy-induced nausea and emesis. Cancer. 2003; 98: 645655.
  • 2
    Multinational Association of Supportive Care in Cancer (MASCC) Antiemetic Guideline Committee. Antiemetic guidelines from the consensus conference on antiemetic therapy. Perugia International Cancer Conference VII, March 29–31, 2004, Perugia, Italy. Available at: [accessed May 2005].
  • 3
    Martin M. The severity and pattern of emesis following different cytotoxic agents Oncology. 1996; 53(Suppl 1): 2631.
  • 4
    Morrow GR, Roscoe JA, Hickok JT, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Huntington). 1998; 12(3 Suppl 4 ): 3237.
  • 5
    Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999; 17: 29712994.
  • 6
    ASHP. American Society for Health-System Pharmacists therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999; 56: 729764.
  • 7
    Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer. 2002; 10: 519522.
  • 8
    Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983; 25(Suppl 1): 17.
  • 9
    Coates A, Abraham S, Kaye SB, et al. On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19: 203208.
  • 10
    Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7: 189195.
  • 11
    de Boer-Dennert M, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer. 1997; 76: 10551061.
  • 12
    Grunberg SM, Srivastava A, Grunberg KJ, Weeks J. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer. 2002; 10: 624629.
  • 13
    Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004; 100: 22612268.
  • 14
    Aventis Pharmaceuticals Inc. Anzemet® (dolasetron mesylate) [prescribing information]. Kansas City: Aventis Pharmaceuticals Inc., 2003.
  • 15
    Novartis Pharmaceuticals Australia Pty Ltd. Navoban® (tropisetron) [prescribing information]. North Ryde: Novartis Pharmaceuticals Australia Pty Ltd., 1997.
  • 16
    MGI Pharma, Inc. Aloxi™ (palonosetron hydrochloride) prescribing information. Bloomington: MGI Pharma, Inc., 2003.
  • 17
    Sanchez LA, Holdsworth M, Bartel SB. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications. Pharmacoeconomics. 2000; 18: 533556.
  • 18
    Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Consensus proposal for 5-HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer. 1998; 6: 237243.
  • 19
    Aapro M. 5-HT3 receptor antagonists: are they all the same? Management of nausea and vomiting: revisiting the role of the 5-HT3 receptor antagonists. Cancer Today. 2002; Suppl 1: 115.
  • 20
    Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999; 3: 113119.
  • 21
    Xu LH, Koch KL, Summy-Long J, et al. Hypothalamic and gastric myoelectrical responses during vection-induced nausea in healthy Chinese subjects. Am J Physiol. 1993; 265: E578E584.
  • 22
    Koffman J, Higginson IJ, Donaldson N. Symptom severity in advanced cancer, assessed in two ethnic groups by interviews with bereaved family members and friends. J R Soc Med. 2003; 96: 1016.
  • 23
    Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003; 8: 187198.
  • 24
    Kris MG, Gralla RJ, Clark RA, Tyson LB. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst. 1989; 81: 4246.
  • 25
    Bonhaus DW, Stefanich E, Loury DN, Hsu SAO, Eglen RM, Wong EHF. Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors. J Neurochem. 1995; 65: 104110.
  • 26
    Parker RMC, Bentley KR, Barnes NM. Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents. TIPS. 1996; 17: 9599.
  • 27
    Bentley KR, Barnes NM. 5-hydroxytryptamine3 (5-HT3) receptor-mediated depolarisation of the rat isolated vagus nerve: modulation by trichloroethanol and related alcohols. Eur J Pharmacol. 1998; 354: 2531.
  • 28
    Sigsgaard T, Herrstedt J, Andersen LJ, et al. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer. 1999; 80: 412418.
  • 29
    Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992; 49: 295304.
  • 30
    Hargreaves AC, Gunthorpe MJ, Taylor CW, Lummis SC. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels. Mol Pharmacol. 1996; 50: 12841294.
  • 31
    van Hooft JA, van der Haar E, Vijverberg HPM. Allosteric potentiation of the 5-HT3 receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. Neuropharmacology. 1997; 36: 649653.
  • 32
    Hu H-Z, Li Z-W. Modulation of nicotine ACh-, GABAA- and 5-HT3-receptor functions by external H-7, a protein kinase inhibitor, in rat sensory neurones. Br J Pharmacol. 1997; 122: 11951201.
  • 33
    Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer. 2002; 10: 139145.
  • 34
    Eiselé J-L, Bertrand S, Galzi J-L, Devillers-Thiéry A, Changeux J-P, Bertrand D. Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature. 1993; 366: 479483.
  • 35
    Steele JA, Martin IL. Interaction of oestrone and 17β-oestradiol with the 5-HT3 receptor. Br J Pharmacol. 1999; 126: 15P.
  • 36
    Andrews PLR, Blower PR. 5-HT3 receptor antagonists and emesis: a pre-clinical review. Pharm Med. 1995; 13: 153191.
  • 37
    Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer. 2001; 9: 442451.
  • 38
    Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002; 20: 28052811.
  • 39
    Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999; 20: 342349.
  • 40
    Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. 2002; 8: 405414.
  • 41
    Jann MW, Cohen LJ. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact. 2000; 16: 3967.
  • 42
    Aapro MS, Selak E, Lichinitser M, Santini D, Macciocchi A. Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): results of a phase III trial [abstract 2918]. Proc Am Soc Clin Oncol. 2003; 22: 726.
  • 43
    Andrews PLR, Bhandari P, Davey PT, Bingham S, Marr HE, Blower PR. Are all 5-HT3 receptor antagonists the same? Eur J Cancer. 1992; 28A(Suppl 1): S2S6.
  • 44
    Riviere A, on behalf of The Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer. 1994; 69: 967971.
  • 45
    Kamanabrou D, on behalf of the Granisetron Study Group. Intravenous granisetron—establishing the optimal dose. Eur J Cancer. 1992; 28A(Suppl 1): S6S11.
  • 46
    Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994; 12: 22042210.
  • 47
    Minami M. Granisetron: is there a dose-response effect on nausea and vomiting? Cancer Chemother Pharmacol. 2003; 52: 8998.
  • 48
    Hacking A, on behalf of the Granisetron Study Group. Oral granisetron—simple and effective: a preliminary report. Eur J Cancer. 1992; 28A(Suppl 1): S28S32.
  • 49
    Bleiberg HH, Spielmann M, Falkson G, Romain D. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose ranging study. Clin Ther. 1995; 17: 3851.
  • 50
    Soukop M, on behalf of the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer. 1994; 2: 177183.
  • 51
    Smith IE, on behalf of the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol. 1993; 119: 350354.
  • 52
    Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol. 1995; 13: 12421248.
  • 53
    Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol. 1996; 14: 22422249.
  • 54
    Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer. 1996; 32A: 807813.
  • 55
    Grote TH, Pineda LF, Figlin RA, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am. 1997; 3: 4551.
  • 56
    Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7: 439445.
  • 57
    Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm. 2000; 57: 16851697.
  • 58
    van Belle SJ, Stamatakis L, Bleiberg H, Cocquyt VF, Michel J, de Bruijn KM. Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol. 1994; 5: 821825.
  • 59
    Wymenga ANM, van der Graaf WTA, Wils JA, et al. A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Ann Oncol. 1996; 7: 505510.
  • 60
    Mantovani G, Macciò A, Bianchi A, et al. Comparison of granisetron, ondansetron and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer. 1996; 77: 941948.
  • 61
    Marty M, Kleisbauer J-P, Fournel P, et al. Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs. 1995; 6(Suppl 1): 1521.
  • 62
    Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol. 1995; 6: 805810.
  • 63
    Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology. 1994; 51: 113118.
  • 64
    Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992; 10: 19691975.
  • 65
    Tsavaris N, Kosmas M, Vadiaka A, et al. Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. J Exp Clin Cancer Res. 2001; 20: 2934.
  • 66
    Grunberg SM. Phase I and other dose-ranging studies of ondansetron. Semin Oncol. 1992; 19(Suppl 10): 1622.
  • 67
    Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. Eur J Cancer. 1993; 29A: 16691672.
  • 68
    Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer. 1992; 66: 192197.
  • 69
    Bosnjak SM, Neskovic-Konstantinovic ZB, Jovanovic-Micic DJ, Mitrovic LB, Radulovic SS. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. J Chemother. 1996; 8: 315318.
  • 70
    Dempsey CL, Coop AJ, Shillington A, Farley PA, Eberhardt DR, O'Briant S. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health Syst Pharm. 2004; 61: 781786.
  • 71
    Jordan K, Hinke A, Grothey A, Schmoll H-J. A meta-analysis comparing the available 5-HT3-receptor antagonists as prophylactic agents for acute chemotherapy-induced emesis [abstract A-29]. Support Care Cancer. 2003; 11: 394.
  • 72
    Needles B, Miranda E, Garcia Rodriguez FM, et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. Support Care Cancer. 1999; 7: 347353.
  • 73
    Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004; 15: 330337.
  • 74
    Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14: 15701577.
  • 75
    Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer. 2003; 98: 24732482.
  • 76
    Wong EHF, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995; 114: 851859.
  • 77
    de Wit R, de Boer AC, van der Linden GHM, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001; 85: 10991101.
  • 78
    Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998; 9: 381385.
  • 79
    Terrey J-P, Aapro MS, on behalf of the Granisetron Study Group. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996; 8: 281288.
  • 80
    Blower P, Aapro M. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? Br J Cancer. 2002; 86: 16621663.
  • 81
    de Wit R. Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer. 2003; 88: 18231827.
  • 82
    Newberry NR, Watkins CJ, Sprosen TS, Blackburn TP, Grahame-Smith DG, Leslie RA. BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology. 1993; 32: 729735.
  • 83
    Upward JW, Arnold BDC, Link C, Pierce DM, Allen A, Tasker TCG. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer. 1990; 26(Suppl 1): S12S15.
  • 84
    Cooper SM, Arnold BDC, Rapeport WG. Inhibition of 5-HT induced axon-reflex flares by BRL 43694, a novel 5-HT3 receptor antagonist. Br J Clin Pharmacol. 1988; 25: 106P107P.
  • 85
    Roche Laboratories. Kytril® (granisetron hydrochloride) [prescribing information]. Nutley: Roche Laboratories Inc., 2001.
  • 86
    GlaxoSmithKline. Zofran® (ondansetron hydrochloride) [prescribing information]. Research Triangle Park: GlaxoSmithKline, 2002.
  • 87
    Sweetland J, Lettis S, Fowler PA, Thomas M. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT-induced flare [abstract]. Br J Clin Pharmacol. 1992; 33: 565P.
  • 88
    Beck TM. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs. 1995; 6: 237242.
  • 89
    Gebauer A, Merger M, Kilbinger H. Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Arch Pharmacol. 1993; 347: 137140.
  • 90
    Blower PR. Differences in anti-emetic predictability among 5-HT3 receptor antagonist drugs. In: DuboisA, KingGL, LivengoodDR, editors. Radiation and the GI tract. Boca Raton: CRC Press Inc, 1995: 3749.
  • 91
    Elliott P, Seemungal BM, Wallis DI. Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide. Naunyn Schmiedebergs Arch Pharmacol. 1990; 341: 503509.
  • 92
    Hesketh PJ, Beck T, Uhlenhopp M, et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol. 1995; 13: 21172122.